Reuters logo
BRIEF-Novo Nordisk: FDA approves label update for obesity drug Saxenda
April 27, 2017 / 3:44 PM / 8 months ago

BRIEF-Novo Nordisk: FDA approves label update for obesity drug Saxenda

April 27 (Reuters) - Danish drug maker Novo Nordisk A/S says:

* Receives approval of Saxenda (liraglutide) injection 3 mg label update including long-term safety and efficacy data from 3-year trial from U.S. Food and Drug Administration

* “We are pleased by the FDA’s approval, which marks Saxenda as the only weight-loss and management medicine in a pen supported by long-term safety and efficacy data,” says Dr. Todd Hobbs, vice president and chief medical officer at Novo Nordisk U.S.

* For more on the data: Further company coverage: (Reporting by Stine Jacobsen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below